These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22394598)

  • 1. ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation.
    Dejean E; Foisseau M; Lagarrigue F; Lamant L; Prade N; Marfak A; Delsol G; Giuriato S; Gaits-Iacovoni F; Meggetto F
    Blood; 2012 May; 119(20):4698-707. PubMed ID: 22394598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
    Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
    Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
    Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
    Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
    Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
    Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
    Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
    Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALCL by any other name: the many facets of anaplastic large cell lymphoma.
    Irshaid L; Xu ML
    Pathology; 2020 Jan; 52(1):100-110. PubMed ID: 31706671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
    Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
    Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
    Horie R; Watanabe M; Ishida T; Koiwa T; Aizawa S; Itoh K; Higashihara M; Kadin ME; Watanabe T
    Cancer Cell; 2004 Apr; 5(4):353-64. PubMed ID: 15093542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of anaplastic large cell lymphoma.
    Zeng Y; Feldman AL
    Leuk Lymphoma; 2016; 57(1):21-7. PubMed ID: 26104084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.
    Wang JC; Zhong LH; Lin WQ; Zhang WF; Xi YF; Liu YP; Zhu Q; Liu W; Zhu WF; Chen YP; Chen G
    Am J Surg Pathol; 2023 Jan; 47(1):55-64. PubMed ID: 36315833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.
    Xing X; Feldman AL
    Adv Anat Pathol; 2015 Jan; 22(1):29-49. PubMed ID: 25461779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
    Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
    Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion.
    Lagarrigue F; Dupuis-Coronas S; Ramel D; Delsol G; Tronchère H; Payrastre B; Gaits-Iacovoni F
    Cancer Res; 2010 Sep; 70(17):6978-87. PubMed ID: 20699364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
    Kutok JL; Aster JC
    J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.